Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 70.4 Billion KRW | -9.24% |
| 2022 | 77.56 Billion KRW | 50.34% |
| 2021 | 51.59 Billion KRW | 16.74% |
| 2020 | 44.19 Billion KRW | 3.5% |
| 2019 | 42.7 Billion KRW | 15.43% |
| 2018 | 36.99 Billion KRW | -38.6% |
| 2017 | 60.25 Billion KRW | 1.94% |
| 2016 | 59.1 Billion KRW | -1.46% |
| 2015 | 59.98 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 74.92 Billion KRW | -10.75% |
| 2024 Q1 | 83.94 Billion KRW | 19.24% |
| 2023 Q2 | 74.27 Billion KRW | -7.97% |
| 2023 Q1 | 80.7 Billion KRW | 4.05% |
| 2023 FY | 70.4 Billion KRW | -9.24% |
| 2023 Q4 | 70.4 Billion KRW | -5.12% |
| 2023 Q3 | 74.2 Billion KRW | -0.1% |
| 2022 Q1 | 86.48 Billion KRW | 67.62% |
| 2022 FY | 77.56 Billion KRW | 50.34% |
| 2022 Q4 | 77.56 Billion KRW | 1.9% |
| 2022 Q3 | 76.12 Billion KRW | 1.09% |
| 2022 Q2 | 75.3 Billion KRW | -12.93% |
| 2021 Q3 | 40.04 Billion KRW | -9.49% |
| 2021 Q4 | 51.59 Billion KRW | 28.83% |
| 2021 FY | 51.59 Billion KRW | 16.74% |
| 2021 Q1 | 53.76 Billion KRW | 21.64% |
| 2021 Q2 | 44.24 Billion KRW | -17.7% |
| 2020 Q3 | 42.24 Billion KRW | 0.19% |
| 2020 Q4 | 44.19 Billion KRW | 4.62% |
| 2020 FY | 44.19 Billion KRW | 3.5% |
| 2020 Q1 | 51.39 Billion KRW | 20.36% |
| 2020 Q2 | 42.16 Billion KRW | -17.96% |
| 2019 Q4 | 42.7 Billion KRW | -14.67% |
| 2019 FY | 42.7 Billion KRW | 15.43% |
| 2019 Q3 | 50.04 Billion KRW | 3.39% |
| 2019 Q1 | 46.01 Billion KRW | 24.37% |
| 2019 Q2 | 48.4 Billion KRW | 5.2% |
| 2018 FY | 36.99 Billion KRW | -38.6% |
| 2018 Q3 | 51.2 Billion KRW | -2.66% |
| 2018 Q4 | 36.99 Billion KRW | -27.76% |
| 2018 Q2 | 52.6 Billion KRW | 0.0% |
| 2017 FY | 60.25 Billion KRW | 1.94% |
| 2016 FY | 59.1 Billion KRW | -1.46% |
| 2015 FY | 59.98 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 9.577% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 92.428% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 90.044% |
| HANDOK Inc. | 449.7 Billion KRW | 84.345% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 17.823% |
| Yuhan Corporation | 712.33 Billion KRW | 90.117% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 88.859% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -342.929% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 91.735% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -31.521% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 65.804% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 6.345% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 52.365% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 9.577% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -93.218% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 71.969% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 68.102% |
| JW Holdings Corporation | 827.51 Billion KRW | 91.492% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 83.89% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 88.002% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.454% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 11.223% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -0.62% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 71.011% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 78.685% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 9.577% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 85.633% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 91.795% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.454% |
| Yuhan Corporation | 712.33 Billion KRW | 90.117% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 85.266% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 48.6% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 86.374% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 81.454% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 54.444% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 21.746% |
| CKD Bio Corp. | 170.76 Billion KRW | 58.772% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 71.116% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 55.345% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -63.651% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 11.223% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 88.87% |
| Boryung Corporation | 373.1 Billion KRW | 81.131% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 66.185% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 65.804% |
| JW Lifescience Corporation | 96.44 Billion KRW | 27.002% |